PL3786162T3 - Pochodne bipirazolu jako inhibitory jak - Google Patents

Pochodne bipirazolu jako inhibitory jak

Info

Publication number
PL3786162T3
PL3786162T3 PL20201593.9T PL20201593T PL3786162T3 PL 3786162 T3 PL3786162 T3 PL 3786162T3 PL 20201593 T PL20201593 T PL 20201593T PL 3786162 T3 PL3786162 T3 PL 3786162T3
Authority
PL
Poland
Prior art keywords
jak inhibitors
bipyrazole derivatives
bipyrazole
derivatives
jak
Prior art date
Application number
PL20201593.9T
Other languages
English (en)
Inventor
Yun-Long Li
Jincong Zhuo
Ding-Quan Qian
Song MEI
Ganfeng Cao
Yongchun Pan
Qun Li
Zhongjiang JIA
Original Assignee
Incyte Holdings Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings Corporation filed Critical Incyte Holdings Corporation
Publication of PL3786162T3 publication Critical patent/PL3786162T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
PL20201593.9T 2013-05-17 2014-05-16 Pochodne bipirazolu jako inhibitory jak PL3786162T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361824683P 2013-05-17 2013-05-17

Publications (1)

Publication Number Publication Date
PL3786162T3 true PL3786162T3 (pl) 2024-04-08

Family

ID=50983151

Family Applications (4)

Application Number Title Priority Date Filing Date
PL14732705T PL2997023T3 (pl) 2013-05-17 2014-05-16 Pochodne bipirazolu jako inhibitory jak
PL17158350T PL3231801T3 (pl) 2013-05-17 2014-05-16 Sol bipirazolu jako inhibitor jak
PL18215671T PL3527263T3 (pl) 2013-05-17 2014-05-16 Pochodne bipirazolu jako inhibitory jak
PL20201593.9T PL3786162T3 (pl) 2013-05-17 2014-05-16 Pochodne bipirazolu jako inhibitory jak

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PL14732705T PL2997023T3 (pl) 2013-05-17 2014-05-16 Pochodne bipirazolu jako inhibitory jak
PL17158350T PL3231801T3 (pl) 2013-05-17 2014-05-16 Sol bipirazolu jako inhibitor jak
PL18215671T PL3527263T3 (pl) 2013-05-17 2014-05-16 Pochodne bipirazolu jako inhibitory jak

Country Status (35)

Country Link
US (7) US9382231B2 (pl)
EP (5) EP3786162B1 (pl)
JP (4) JP6415543B2 (pl)
KR (2) KR102442747B1 (pl)
CN (2) CN105452239B (pl)
AR (2) AR096330A1 (pl)
AU (5) AU2014265279B2 (pl)
BR (1) BR112015028501B8 (pl)
CA (1) CA2911536C (pl)
CL (1) CL2015003355A1 (pl)
CR (2) CR20190156A (pl)
CY (3) CY1119105T1 (pl)
DK (3) DK3231801T3 (pl)
EA (2) EA036448B1 (pl)
ES (4) ES2960731T3 (pl)
FI (1) FI3786162T3 (pl)
HK (2) HK1221466A1 (pl)
HR (4) HRP20231048T1 (pl)
HU (4) HUE063817T2 (pl)
IL (4) IL242453B (pl)
LT (4) LT2997023T (pl)
ME (2) ME02763B (pl)
MX (2) MX2020004506A (pl)
MY (1) MY174788A (pl)
PE (2) PE20160126A1 (pl)
PH (2) PH12015502563A1 (pl)
PL (4) PL2997023T3 (pl)
PT (4) PT2997023T (pl)
RS (4) RS56012B1 (pl)
SG (2) SG11201509180WA (pl)
SI (4) SI3786162T1 (pl)
TR (1) TR201905814T4 (pl)
TW (2) TWI664176B (pl)
UA (1) UA117830C2 (pl)
WO (1) WO2014186706A1 (pl)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2455382T3 (da) 2005-12-13 2017-01-02 Incyte Holdings Corp Heteroaryl substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus kinase-inhibitorer
PT3070090T (pt) 2007-06-13 2019-03-20 Incyte Holdings Corp Utilização de sais do inibidor da janus cinase (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2761954C (en) 2009-05-22 2018-07-31 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SG183551A1 (en) 2010-03-10 2012-10-30 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
SG185567A1 (en) 2010-05-21 2012-12-28 Incyte Corp Topical formulation for a jak inhibitor
UA113156C2 (xx) 2010-11-19 2016-12-26 Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
US9096600B2 (en) 2010-12-20 2015-08-04 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
JP5876146B2 (ja) 2011-06-20 2016-03-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
BR112014004971B1 (pt) 2011-09-02 2021-02-09 Incyte Holdings Corporation compostos heterociclilaminas, sua composição farmacêutica e seus usos
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP2917221A1 (en) 2012-11-01 2015-09-16 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
EP2919766B1 (en) 2012-11-15 2021-05-26 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
UA121532C2 (uk) 2013-03-06 2020-06-10 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
EP3786162B1 (en) 2013-05-17 2023-08-09 Incyte Holdings Corporation Bipyrazole derivatives as jak inhibitors
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
MX2016011103A (es) * 2014-02-28 2017-02-28 Incyte Corp Inhibidores de cinasa janus 1 (jak1) para el tratamiento de sindromes mielodisplasicos.
RS61058B1 (sr) 2014-04-08 2020-12-31 Incyte Corp Lečenje b-ćelijskih maligniteta sa kombinacijom inhibitora jak i pi3k
SG10201809518QA (en) 2014-04-30 2018-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
WO2015184305A1 (en) * 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
SI3831833T1 (sl) 2015-02-27 2023-03-31 Incyte Holdings Corporation Postopki za pripravo inhibitorja PI3K
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN107847432A (zh) * 2015-05-29 2018-03-27 西德奈克西斯公司 D2o稳定化的药物制剂
MA43169B1 (fr) 2015-11-06 2022-05-31 Incyte Corp Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
TW201734003A (zh) 2016-01-05 2017-10-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之吡啶及嘧啶化合物
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
CN107759623B (zh) * 2016-08-23 2020-08-14 苏州旺山旺水生物医药有限公司 Jak抑制剂的中间体及其制备方法
EP4198036A1 (en) * 2016-09-06 2023-06-21 F. Hoffmann-La Roche AG 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a] pyridinyl compounds, compositions and methods of use thereof
HUE056615T2 (hu) 2017-10-18 2022-02-28 Incyte Corp Tercier hidroxicsoportokkal szubsztituált kondenzált imidazol-származékok mint PI3K-gamma inhibitorok
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CR20200379A (es) 2018-01-30 2021-03-05 Incyte Corp Procesos e intermedio para elaborar un inhibidor de jak campo técnico
CA3091339A1 (en) 2018-02-16 2019-08-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of cytokine-related disorders
IL302865A (en) * 2018-03-30 2023-07-01 Incyte Corp Use of JAK inhibitors to treat hidradenitis suppurativa
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
US11372003B2 (en) 2018-04-13 2022-06-28 Incyte Corporation Biomarkers for graft-versus-host disease
CN108484468A (zh) * 2018-05-11 2018-09-04 南京大学 芳基氮杂环丁烷类化合物的制备方法
WO2020051169A1 (en) 2018-09-05 2020-03-12 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
WO2020092726A1 (en) 2018-10-31 2020-05-07 Incyte Corporation Combination therapy for treatment of hematological diseases
CN113692278A (zh) 2018-12-19 2021-11-23 因赛特公司 用于治疗胃肠道疾病的jak1途径抑制剂
US11406640B2 (en) 2019-03-05 2022-08-09 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
JP2022526301A (ja) 2019-03-19 2022-05-24 インサイト・コーポレイション 尋常性白斑のバイオマーカー
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021072116A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
US20210123931A1 (en) 2019-10-10 2021-04-29 Incyte Corporation Biomarkers for graft-versus-host disease
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
MX2022015221A (es) 2020-06-02 2023-03-08 Incyte Corp Procesos para preparar un inhibidor de cinasa jano 1 (jak1).
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
KR20230096973A (ko) 2020-08-18 2023-06-30 인사이트 코포레이션 Jak 저해제를 제조하기 위한 방법 및 중간체
AU2021329301A1 (en) 2020-08-18 2023-04-13 Incyte Corporation Process and intermediates for preparing a JAK1 inhibitor
CN112159394B (zh) * 2020-10-09 2021-10-22 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
CA3204186A1 (en) 2020-12-04 2022-06-09 Incyte Corporation Jak inhibitor with a vitamin d analog for treatment of skin diseases
KR20230118118A (ko) 2020-12-08 2023-08-10 인사이트 코포레이션 백반증의 치료를 위한 jak1 경로 저해제
CN114081889A (zh) * 2020-12-29 2022-02-25 上海岸阔医药科技有限公司 预防或治疗egfr功能异常相关的副作用的方法
CA3207859A1 (en) 2021-01-11 2022-07-14 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor
WO2022235613A1 (en) 2021-05-03 2022-11-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of prurigo nodularis
WO2024030600A1 (en) 2022-08-05 2024-02-08 Incyte Corporation Treatment of urticaria using jak inhibitors
CN117186078A (zh) * 2023-11-06 2023-12-08 药康众拓(北京)医药科技有限公司 氘代氮杂环丁烷类jak抑制剂药物及用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5646749A (en) * 1979-09-26 1981-04-28 Mitsui Toatsu Chemicals Protective sheet for surface
JPS60106847U (ja) 1983-12-27 1985-07-20 富士重工業株式会社 室外後写鏡
JP2650681B2 (ja) 1987-07-10 1997-09-03 株式会社ブリヂストン 空気ばね
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US20040089753A1 (en) 2000-06-28 2004-05-13 Holland Simon Joseph Wet milling process
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
EP1441737B1 (en) 2001-10-30 2006-08-09 Novartis AG Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
JP2008520612A (ja) 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト ＪＡＫ阻害剤およびＢｃｒ−Ａｂｌ、Ｆｌｔ−３、ＦＡＫまたはＲＡＦキナーゼ阻害剤のうち少なくとも１個の組合せ
DK2455382T3 (da) 2005-12-13 2017-01-02 Incyte Holdings Corp Heteroaryl substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus kinase-inhibitorer
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
PT3070090T (pt) 2007-06-13 2019-03-20 Incyte Holdings Corp Utilização de sais do inibidor da janus cinase (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo
CA2704599C (en) * 2007-11-16 2015-05-12 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
EA017218B1 (ru) * 2008-03-11 2012-10-30 Инсайт Корпорейшн Производные азетидина и циклобутана как ингибиторы jak-киназ
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
CA2761954C (en) 2009-05-22 2018-07-31 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN102596960B (zh) 2009-10-09 2016-01-20 因西特控股公司 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
EA023444B1 (ru) 2010-02-18 2016-06-30 Инсайт Холдингс Корпорейшн Циклобутановые и метилциклобутановые производные, композиции на их основе и способы их применения
SG183551A1 (en) 2010-03-10 2012-10-30 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
AU2011240808B2 (en) * 2010-04-14 2015-01-22 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases
SG185567A1 (en) 2010-05-21 2012-12-28 Incyte Corp Topical formulation for a jak inhibitor
UA113156C2 (xx) * 2010-11-19 2016-12-26 Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
ES2545110T3 (es) 2010-12-10 2015-09-08 Rottapharm Biotech S.R.L. Derivados de piridinamida como antagonistas del receptor EP4
US9926601B2 (en) 2011-02-24 2018-03-27 Massachusetts Institute Of Technology Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer
JP5876146B2 (ja) * 2011-06-20 2016-03-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) * 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EP2758051B1 (en) 2011-09-22 2018-04-11 Merck Sharp & Dohme Corp. Cyanomethylpyrazole carboxamides as janus kinase inhibitors
TW201406761A (zh) * 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP2917221A1 (en) 2012-11-01 2015-09-16 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
EP2919766B1 (en) 2012-11-15 2021-05-26 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
UA121532C2 (uk) 2013-03-06 2020-06-10 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
AU2014267198A1 (en) 2013-05-17 2015-11-05 F. Hoffmann-La Roche Ag 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
EP3786162B1 (en) 2013-05-17 2023-08-09 Incyte Holdings Corporation Bipyrazole derivatives as jak inhibitors
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
MX2016011103A (es) 2014-02-28 2017-02-28 Incyte Corp Inhibidores de cinasa janus 1 (jak1) para el tratamiento de sindromes mielodisplasicos.
SG10201809518QA (en) 2014-04-30 2018-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
ES2756300T3 (es) 2014-12-16 2020-04-27 Novartis Ag Compuestos de ácido isoxazol hidroxámico como inhibidores de LpxC
MX2022015221A (es) 2020-06-02 2023-03-08 Incyte Corp Procesos para preparar un inhibidor de cinasa jano 1 (jak1).
CA3204186A1 (en) 2020-12-04 2022-06-09 Incyte Corporation Jak inhibitor with a vitamin d analog for treatment of skin diseases

Also Published As

Publication number Publication date
EP3527263A1 (en) 2019-08-21
KR102341908B1 (ko) 2021-12-23
SI2997023T1 (sl) 2017-07-31
HRP20210119T1 (hr) 2021-03-05
CY1121763T1 (el) 2020-07-31
ES2626793T3 (es) 2017-07-26
BR112015028501A2 (pt) 2017-07-25
PT3527263T (pt) 2021-02-01
LT3527263T (lt) 2021-05-10
SI3231801T1 (sl) 2019-05-31
JP2021008493A (ja) 2021-01-28
US20200010456A1 (en) 2020-01-09
MX2020004506A (es) 2021-08-09
IL242453B (en) 2019-11-28
PH12018502125A1 (en) 2019-03-25
NZ753638A (en) 2020-11-27
CR20190156A (es) 2019-05-16
IL282644A (en) 2021-06-30
ES2720073T3 (es) 2019-07-17
SI3786162T1 (sl) 2024-02-29
US20240150327A1 (en) 2024-05-09
PT2997023T (pt) 2017-05-31
AR096330A1 (es) 2015-12-23
EP4275756A3 (en) 2024-02-07
EP3231801A1 (en) 2017-10-18
RS58743B1 (sr) 2019-06-28
CR20150633A (es) 2016-04-05
WO2014186706A1 (en) 2014-11-20
ES2845210T3 (es) 2021-07-26
JP6775560B2 (ja) 2020-10-28
US10435392B2 (en) 2019-10-08
TW201940479A (zh) 2019-10-16
ES2960731T3 (es) 2024-03-06
EA039660B1 (ru) 2022-02-24
EP3786162A1 (en) 2021-03-03
IL264409A (en) 2019-02-28
HRP20170795T1 (hr) 2017-08-25
CN107698569A (zh) 2018-02-16
EP3527263B1 (en) 2020-10-28
AU2022263454B2 (en) 2024-01-18
US20210238168A1 (en) 2021-08-05
AU2020202000B2 (en) 2021-03-11
CY1123756T1 (el) 2022-05-27
HUE063817T2 (hu) 2024-01-28
AU2020202000A1 (en) 2020-04-09
MX2015015738A (es) 2016-03-16
TW201512191A (zh) 2015-04-01
BR112015028501B1 (pt) 2022-11-01
LT3786162T (lt) 2023-11-27
PL3231801T3 (pl) 2019-07-31
SG10201709469SA (en) 2017-12-28
JP2019011364A (ja) 2019-01-24
AU2014265279B2 (en) 2018-09-27
DK3231801T3 (en) 2019-04-15
PE20200527A1 (es) 2020-03-09
PL2997023T3 (pl) 2017-08-31
US9926301B2 (en) 2018-03-27
RS56012B1 (sr) 2017-09-29
NZ753639A (en) 2020-11-27
EA201592199A1 (ru) 2016-05-31
KR20210120120A (ko) 2021-10-06
US20140343030A1 (en) 2014-11-20
KR20220127371A (ko) 2022-09-19
JP2022163162A (ja) 2022-10-25
TR201905814T4 (tr) 2019-05-21
AU2021202685B2 (en) 2022-11-17
ME02763B (me) 2018-01-20
ME03355B (me) 2019-10-20
HRP20190713T1 (hr) 2019-06-14
TWI719401B (zh) 2021-02-21
US11001571B2 (en) 2021-05-11
TW202116320A (zh) 2021-05-01
CN105452239B (zh) 2017-11-21
PH12015502563B1 (en) 2016-02-22
AU2018223058B2 (en) 2020-01-02
DK3786162T3 (da) 2023-10-09
FI3786162T3 (fi) 2023-10-02
TWI664176B (zh) 2019-07-01
AU2014265279A1 (en) 2015-11-26
US11905275B2 (en) 2024-02-20
IL264409B (en) 2021-05-31
IL282644B (en) 2021-10-31
PE20160126A1 (es) 2016-02-24
EA202090291A3 (ru) 2020-06-30
SG11201509180WA (en) 2015-12-30
NZ753637A (en) 2020-11-27
JP6415543B2 (ja) 2018-10-31
EP2997023A1 (en) 2016-03-23
US20230159501A1 (en) 2023-05-25
RS64591B1 (sr) 2023-10-31
KR20160019905A (ko) 2016-02-22
UA117830C2 (uk) 2018-10-10
IL287313B (en) 2022-03-01
HK1221466A1 (zh) 2017-06-02
AR118120A2 (es) 2021-09-22
DK3527263T3 (da) 2021-01-25
NZ753636A (en) 2020-11-27
CN107698569B (zh) 2020-11-27
EA202090291A2 (ru) 2020-05-31
SI3527263T1 (sl) 2021-05-31
AU2018223058A1 (en) 2018-09-20
EP3786162B1 (en) 2023-08-09
MY174788A (en) 2020-05-14
HUE043573T2 (hu) 2019-08-28
JP7126741B2 (ja) 2022-08-29
PH12015502563A1 (en) 2016-02-22
US20180312492A1 (en) 2018-11-01
BR112015028501B8 (pt) 2023-01-24
AU2021202685A1 (en) 2021-05-27
PL3527263T3 (pl) 2021-05-17
AU2022263454A1 (en) 2022-12-08
US20160289215A1 (en) 2016-10-06
CL2015003355A1 (es) 2016-05-27
US9382231B2 (en) 2016-07-05
PT3231801T (pt) 2019-05-24
CN105452239A (zh) 2016-03-30
HUE033587T2 (hu) 2017-12-28
LT3231801T (lt) 2019-08-12
HRP20231048T1 (hr) 2023-12-22
HUE053122T2 (hu) 2021-06-28
EP4275756A2 (en) 2023-11-15
CY1119105T1 (el) 2018-02-14
CA2911536A1 (en) 2014-11-20
EA036448B1 (ru) 2020-11-11
JP2016519147A (ja) 2016-06-30
EP2997023B9 (en) 2018-06-13
KR102442747B1 (ko) 2022-09-14
EP3231801B1 (en) 2019-02-13
HK1245769B (zh) 2020-02-07
CA2911536C (en) 2021-07-20
LT2997023T (lt) 2017-06-26
PT3786162T (pt) 2023-10-20
EP2997023B1 (en) 2017-03-22
IL287313A (en) 2021-12-01
US11591318B2 (en) 2023-02-28
NZ713999A (en) 2020-11-27
RS61482B1 (sr) 2021-03-31

Similar Documents

Publication Publication Date Title
HK1221466A1 (zh) 作為 抑制劑的聯吡唑衍生物
HK1215795A1 (zh) 鵝膏毒素衍生物
LT2953944T (lt) Piridazinono amidų dariniai
HK1216531A1 (zh) 新的抑制劑
PL3027598T3 (pl) Pochodne oksochinazolinylo-butanoamidowe
PL3087076T3 (pl) Pochodne imidazopirazynonowe
IL240763B (en) The halopyrazoles as thrombin inhibitors
HK1213566A1 (zh) 新的四唑酮衍生物